CANDEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Candex, and when can generic versions of Candex launch?
Candex is a drug marketed by Bayer Pharms and is included in two NDAs.
The generic ingredient in CANDEX is nystatin. There is one drug master file entry for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the nystatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Candex
A generic version of CANDEX was approved as nystatin by FOUGERA PHARMS on September 23rd, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CANDEX?
- What are the global sales for CANDEX?
- What is Average Wholesale Price for CANDEX?
Summary for CANDEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 124 |
| Patent Applications: | 4,155 |
| DailyMed Link: | CANDEX at DailyMed |
US Patents and Regulatory Information for CANDEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Pharms | CANDEX | nystatin | CREAM;TOPICAL | 061810-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Pharms | CANDEX | nystatin | LOTION;TOPICAL | 050233-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
